Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial

​

Vasomune Therapeutics has completed enrolment in its AV001-004 Phase IIa trial assessing Pegevongitide in patients hospitalised with pneumonia requiring supplemental oxygen.

The post Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.